Correction: Preadmission medications and recent falls in older inpatients: an observational study
Louise Clarkson, Anthony Griffiths, Shu‑Kay Ng, Alfred K. Lam, Tien K. Khoo
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Practices and Patient Outcomes
Correction to: International Journal of Clinical Pharmacy 10.1007/s11096-024-01859-y
In Table 2 of this article, the data under the row “Antihypertensive Medication” and their values were aligned incorrectly.
For completeness and transparency, the old incorrect version and the corrected version of Table 2 are displayed below
The original article has been corrected.
Incorrect version of Table 2
Table 2 Pharmacological treatment on admissionAll participants (n = 194)Participants with no falls (n = 87, 44.8%)Participants with one or more falls (n = 107, 55.2%)p-valueDBI = 0100 (51.5%)50 (57.5%)50 (46.7%)p = 0.136DBI ≥ 140 (20.6%)14 (16.1%)26 (24.3%)p = 0.160AEC ≥ 240 (20.6%)12 (13.8%)28 (26.2%) p ** = 0.034** Antihypertensive Medication-Thiazides and related antihypertensives ACEI’s ARBS CCB’s BB’s Other antihypertensives19 (9.8%) 51 (26.3%) 55 (28.4%) 43 (22.2%) 78 (40.2%) 16 (8.2%)10 (11.5%) 26 (29.9%) 28 (32.2%) 21 (24.1%) 42 (48.3%) 8 (9.2%)9 (8.4%) 25 (23.4%) 27 (25.2%) 22 (20.6%) 36 (33.6%) 8 (7.5%)p = 0.472 p = 0.305p = 0.285 p = 0.551 p** = 0.039** p = 0.665Statin Use104 (53.6%)53 (60.9%)51 (47.7%)p = 0.066Proton Pump Inhibitor Use86 (44.3%)36 (41.4%)50 (46.7%)p = 0.456Anticoagulant Use51 (26.3%)23 (26.4%)28 (26.2%)p = 0.966Antiplatelet Use74 (38.1%)38 (43.7%)36 (33.6%)p = 0.152ACEI Angiotensin-Converting Enzyme Inhibitor, ARB Angiotensin Receptor Blocker, CCB Calcium Channel Blocker, BB Betablockers
The correct version of Table 2
Table 2 Pharmacological treatment on admissionAll participants (n = 194)Participants with no falls (n = 87, 44.8%)Participants with one or more falls (n = 107, 55.2%)p-valueDBI = 0100 (51.5%)50 (57.5%)50 (46.7%)p = 0.136DBI ≥ 140 (20.6%)14 (16.1%)26 (24.3%)p = 0.160AEC ≥ 240 (20.6%)12 (13.8%)28 (26.2%) p ** = 0.034** Antihypertensive Medication Thiazides and related antihypertensives19 (9.8%)10 (11.5%)9 (8.4%)p = 0.472 ACEI’s51 (26.3%)26 (29.9%)25 (23.4%)p = 0.305 ARBS55 (28.4%)28 (32.2%)27 (25.2%)p = 0.285 CCB’s43 (22.2%)21 (24.1%)22 (20.6%)p = 0.551 BB’s78 (40.2%)42 (48.3%)36 (33.6%) p ** = 0.039** Other antihypertensives16 (8.2%)8 (9.2%)8 (7.5%)p = 0.665Statin Use104 (53.6%)53 (60.9%)51 (47.7%)p = 0.066Proton Pump Inhibitor Use86 (44.3%)36 (41.4%)50 (46.7%)p = 0.456Anticoagulant Use51 (26.3%)23 (26.4%)28 (26.2%)p = 0.966Antiplatelet Use74 (38.1%)38 (43.7%)36 (33.6%)p = 0.152ACEI Angiotensin-Converting Enzyme Inhibitor, ARB Angiotensin Receptor Blocker, CCB Calcium Channel Blocker, BB Betablockers